Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Hasenkamp

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Annals of Hematology|May 29, 2026
Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysisAlexander C Angleitner, Markus Maulhardt, Hannes Treiber, et al.
Ejhaem|June 8, 2026
Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell EraEnver Aydilek, Paolo Mazzeo, Justin Hasenkamp, et al.
Leukemia & Lymphoma|December 11, 2024
Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioningEvgenii Shumilov, Lena Levien, Paolo Mazzeo, et al.
Advances in Hematology|May 7, 2020
Dental and Periodontal Treatment Need after Dental Clearance Is Not Associated with the Outcome of Induction Therapy in Patients with Acute Leukemia: Results of a Retrospective Pilot StudyGerhard Schmalz, Lulzim Tulani, Rilana Busjan, et al.
European Journal of Haematology|March 30, 2026
Long-Term Clinical and Molecular Dynamics in Hypoplastic Myelodysplastic Neoplasia Treated With Immunosuppressive TherapyHannes Treiber, Christina Ganster, Katayoon Shirneshan, et al.
Annals of Hematology|April 28, 2017
Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokinesHolger Budde, Susanne Papert, Jens-Holger Maas, et al.
Current Oncology (Toronto, Ont.)|January 20, 2023
Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell TherapyLea Naomi Eder, Danilo Martinovic, Paolo Mazzeo, et al.
Annals of Hematology|March 2, 2011
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescueKarin Hohloch, Carsten Oliver Sahlmann, Vijai J Lakhani, et al.
Hematological Oncology|April 3, 2022
Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysisEvgenii Shumilov, Justin Hasenkamp, Markus Maulhardt, et al.
Annals of Hematology|April 15, 2025
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)Stephan Fuhrmann, Maike Nickelsen, Justin Hasenkamp, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Annals of Hematology|May 29, 2026
Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysisAlexander C Angleitner, Markus Maulhardt, Hannes Treiber, et al.
Ejhaem|June 8, 2026
Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell EraEnver Aydilek, Paolo Mazzeo, Justin Hasenkamp, et al.
Leukemia & Lymphoma|December 11, 2024
Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioningEvgenii Shumilov, Lena Levien, Paolo Mazzeo, et al.
Advances in Hematology|May 7, 2020
Dental and Periodontal Treatment Need after Dental Clearance Is Not Associated with the Outcome of Induction Therapy in Patients with Acute Leukemia: Results of a Retrospective Pilot StudyGerhard Schmalz, Lulzim Tulani, Rilana Busjan, et al.
European Journal of Haematology|March 30, 2026
Long-Term Clinical and Molecular Dynamics in Hypoplastic Myelodysplastic Neoplasia Treated With Immunosuppressive TherapyHannes Treiber, Christina Ganster, Katayoon Shirneshan, et al.
Annals of Hematology|April 28, 2017
Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokinesHolger Budde, Susanne Papert, Jens-Holger Maas, et al.
Current Oncology (Toronto, Ont.)|January 20, 2023
Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell TherapyLea Naomi Eder, Danilo Martinovic, Paolo Mazzeo, et al.
Annals of Hematology|March 2, 2011
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescueKarin Hohloch, Carsten Oliver Sahlmann, Vijai J Lakhani, et al.
Hematological Oncology|April 3, 2022
Outcomes of second allogeneic stem cell transplantation and anti-relapse strategies in patients with relapsed/refractory acute myeloid leukemia: A unicentric retrospective analysisEvgenii Shumilov, Justin Hasenkamp, Markus Maulhardt, et al.
Annals of Hematology|April 15, 2025
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)Stephan Fuhrmann, Maike Nickelsen, Justin Hasenkamp, et al.
Pageof 4